Atazanavir

Excerpt

Atazanavir is approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV-1 infection in both treatment-naive and treatment-experienced patients. This medication is prescribed in combination with other antiretroviral agents for individuals aged 3 months and older with a body weight of 5 kg or more. Atazanavir belongs to the protease inhibitor class of HIV-1 medications and is occasionally used off-label for HIV postexposure prophylaxis in situations involving potential exposure, such as needle sticks. This activity highlights the indications, mechanism of action, administration, adverse effects, contraindications, and monitoring for atazanavir, providing relevant information for healthcare team members involved in the management of HIV/AIDS infection.